CLIA Certification for Alzheimer's Biomarkers at the Glenn Biggs Institute in San Antonio, TX
With our certificate of compliance, we can now return Fujirebio Lumipulse AB 42:40 biomarker results to clinicians and research studies to aid in clinical diagnosis of AD. CLIA approval guarantees that biomarker assays demonstrate consistent performance in clinical settings, addressing variability across different laboratories and patient populations, which we found to be true for the Fujirebio CSF AB42:40 biomarker test. CLIA approval is an essential step in making AD biomarkers accessible for routine clinical application, as well as precision medicine approaches and enhancing early diagnosis and intervention strategies for Alzheimer's Disease.
Authors
- Oluwaseun Ogunbona (ORCID: https://orcid.org/0000-0001-5116-7204)
- Tiffany F. Kautz (ORCID: https://orcid.org/0000-0001-7680-4708)
- Eric L. Shipp
- Julie Parker‐Garza
- Margaret E Flanagan
- Sudha Seshadri
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Institute for Neurodegenerative Disorders (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_101042
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00